

Technology Advisory Interests Register

Topic: Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Mike Chambers	TAC Committee Member	Financial	I have participated in an advisory board for Accord (possible comparator company) in an unrelated disease area: small-cell lung cancer	23/09/2025 14/04/2026	It was agreed that Mike's declaration would not prevent them from participating in discussions on this appraisal
Elizabeth Thurgar	TAC Committee Member	Financial	I am currently working with Takeda, a listed comparator company, in an unrelated indication, central disorders of hypersomnolence	23/09/2025 14/04/2026	It was agreed that Elizabeth's declaration would not prevent them from participating in discussions on this appraisal
Pedro Saramago Goncalves	TAC Committee Member	Financial	I would like to declare that I have done some health economics private consulting work in an advisory capacity for accord healthcare on an unrelated disease area - lung cancer.	24/09/2025	It was agreed that Pedro's declaration would not prevent them from participating in discussions on this appraisal
Clare Offer	TAC Committee Member	Non-financial professional	As part of my employment with NHS England I am the public health representative on the national Clinical Reference Group for allergy and immunology, which includes services for HAE. I have had no involvement with the submission for	25/09/2025	It was agreed that Clare's declaration would not prevent them from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Sebetralstat and receive no additional payment for my role on the CRG.		
Dr Prithwiraj Das	TAC Committee Member	Non-financial professional	I work in life sciences, including pharmaceutical market access, as Founding Director of G2PR Ltd. I have not worked on these products/indications in the last 12+ months	29/09/2025	It was agreed that Prithwiraj's declaration would not prevent them from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Financial	Regeneron is developing REGN9533 targeting factor XII and in collaboration with Alnylam developing ALN-F1202 targeting factor XII. I work for Regeneron, pharmaceuticals/biotech company. I also own shares in the company and have stock options.	23/09/2025 22/04/2026	It was agreed that Satish's declaration would prevent them from participating in discussions on this appraisal
Dr Patrick Yong	Expert	Direct - financial	I have received consulting fees, honoraria and/or support for attending meetings from Astria Therapeutics, Biocryst, CSL Behring, Kalvista, Novartis, Otsuka, Pharming, Pharvaris, Takeda	28/04/2025 05/05/2026	It was agreed that Patrick's declaration would not prevent them from providing expert advice to the committee.
Professor Sinisa Savic	Expert	Direct - financial	I have received remuneration for participating in advisory board meetings from the following organisations in the last 12 months: KalVista, CSL Behring, Phavaris, Celldex, Novartis, SOBI, Pharming, Otsuka.	23/05/2025 05/05/2026	It was agreed that Sinisa's declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Research grants: CSL Behring, Takeda, Pharming Educational events: Takeda, KalVista, Pharming, SOBI, Novartis Trial steering committee: SOBI Data monitoring committee: Octopharma		
		Direct – non-financial	I chair British society for Immunology clinical immunology professional network, and I am also a trustee of BSI		
Angela Metcalfe	Expert	Direct - financial	Unrestricted grants in the financial year ended September 2023 (last audited accounts) to HAE UK CSL Behring £35,000 Takeda UK £3,000 BioCryst Pharmaceuticals £16,500	29/04/2025 05/05/2026	It was agreed that Angela's declaration would not prevent them from providing expert advice to the committee.